Biocartis Group Dividendos y recompras

Dividendo controles de criterios 0/6

Biocartis Group no tiene historial de pago de dividendo.

Información clave

n/a

Rentabilidad por dividendo

-84.7%

Rendimiento de la recompra

Rendimiento total para el accionista	-84.7%
Rendimiento futuro de los dividendos	n/a
Crecimiento de los dividendos	n/a
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Ratio de pago	n/a

Últimas actualizaciones de dividendos y recompras

No hay actualizaciones

Recent updates

Investors Give Biocartis Group NV (EBR:BCART) Shares A 31% Hiding

Jun 17

Analysts Have Been Trimming Their Biocartis Group NV (EBR:BCART) Price Target After Its Latest Report

Feb 27

What Type Of Returns Would Biocartis Group's(EBR:BCART) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Jul 28

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de BCART han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de BCART han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Biocartis Group vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de BCART con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (BCART)	n/a
Suelo de mercado 25% (BE)	2.8%
Techo de mercado 25% (BE)	7.7%
Media de la industria (Medical Equipment)	1.6%
Analista de previsiones (BCART) (hasta 3 años)	n/a

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de BCART en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de BCART en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de BCART para determinar si sus pagos de dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que BCART no ha comunicado ningún pago.

Biocartis Group Dividendos y recompras

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos y recompras

Recent updates

Biocartis Group Ordinary Shares to be Deleted from OTC Equity

New major risk - Financial data availability

New minor risk - Financial data availability

Biocartis Group NV Presents Four Abstracts Showing Excellent Data for Idylla at European Society of Molecular Oncology Congress

First half 2023 earnings released

Biocartis Appoints New Medical Advisory Board (Mab) of Renowned Practice Leaders

Biocartis Group NV to Report First Half, 2023 Results on Sep 26, 2023

Biocartis Group NV Appoints George Cardoza as Chief Financial Officer, Effective 7 August 2023

Investors Give Biocartis Group NV (EBR:BCART) Shares A 31% Hiding

New major risk - Share price stability

Biocartis Group NV Announces Resignation of Jean-Marc Roelandt as CFO

Full year 2022 earnings released: €0.79 loss per share (vs €1.24 loss in FY 2021)

Full year 2022 earnings released: €0.79 loss per share (vs €1.24 loss in FY 2021)

Biocartis Group NV Announces the Launch of the First Assay Developed With the New Idylla™ Flex Technology

Biocartis Group NV has completed a Follow-on Equity Offering in the amount of €25.107699 million.

Price target decreased to €4.75

Insufficient new directors

Biocartis Group NV Announces New Idylla™ EGFR Study Shows Reduction of Time-To-Treatment by 48% for Lung Cancer Patients

Biocartis Group NV Announces New Idylla™ EGFR Study Shows Reduction of Time-To-Treatment by 48% for Lung Cancer Patients

Biocartis Group NV to Report Q1, 2023 Results on Apr 20, 2023

First half 2022 earnings released: EPS: €0 (vs €0.65 loss in 1H 2021)

Biocartis Group NV Provides Earnings Guidance for 2022

Biocartis Group NV Obtains ISO 27001 Certification for Information Security Management

Biocartis Group NV Announces Launch of its Rapid CE-marked IVD Idylla GeneFusion Panel for Fast Treatment Decisions in Lung Cancer

Biocartis Group NV announces New Study Led by Memorial Sloan Kettering Cancer Center (NY, US) Shows Idylla™ Genefusion Assay Enables More Rapid Screening of Targetable Fusions Compared to Routine Methods

Price target decreased to €4.75

Insufficient new directors

Biocartis Group NV Reconfirms Earnings Guidance of 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Analysts Have Been Trimming Their Biocartis Group NV (EBR:BCART) Price Target After Its Latest Report

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Biocartis Group NV Provides Earnings Guidance for the Year 2022

Biocartis Group NV Announces Publication of Large New Study Comparing the Difference in Turnaround Time Between In-House Automated Rapid Pcr3-Based EGFR Analysis and Next-Generation Sequencing

Price target decreased to €6.50

Insufficient new directors

Biocartis’ Idylla™ SARS-CoV-2 Testing Successfully Detects Omicron Variant

Biocartis Group NV Announces Restart of Its High-Throughput Cartridge Manufacturing Line

Biocartis Group NV Receives EUR 1.4 Million Grant to Support Development of New Idylla™ Technology

Biocartis Group NV Reconfirms Production Guidance of 2021

Full year 2020 earnings released: €1.11 loss per share (vs €1.14 loss in FY 2019)

We Think Biocartis Group (EBR:BCART) Has A Fair Chunk Of Debt

Full year 2020 earnings released: €1.11 loss per share (vs €1.14 loss in FY 2019)

New 90-day low: €4.41

Revenue and earnings beat expectations

What Kind Of Shareholders Own Biocartis Group NV (EBR:BCART)?

What We Learned About Biocartis Group's (EBR:BCART) CEO Compensation

Biocartis Group NV Announces Ten Idylla™ Studies to be Published at Virtual AMP (US) Annual Meeting

Biocartis Group NV Announces Publication of Large Multi-Center Comparison Study with Idylla™ MSI Assay

Biocartis Group NV to Report Q3, 2021 Results on Nov 10, 2021

Biocartis and Geneprodx to Collaborate on Fully Automated Thyroidprint Test on Idylla

Biocartis Group NV Announces Partnership with Endpoint Health to Develop Novel Companion Diagnostic in Critical Illness

Price target lowered to €7.75

New 90-day low: €4.16

Biocartis Group Nv Announces Market Release of Septicyte® Rapid Test on Idylla™

First half earnings released

Biocartis Group NV to Report Fiscal Year 2020 Final Results on Apr 01, 2021

New 90-day high - €5.02

What Can We Learn About Biocartis Group's (EBR:BCART) CEO Compensation?

New 90-day high - €5.01

What Type Of Returns Would Biocartis Group's(EBR:BCART) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Estabilidad y crecimiento de los pagos

Rentabilidad por dividendo vs. Mercado

Pago de beneficios a los accionistas

Pago en efectivo a los accionistas

Descubre empresas que pagan buenos dividendos